Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 19/20 | 0.73 |
| ▸ | BRD9 | Q9H8M2 | 3/20 | 0.73 |
| ▸ | KAT2A | Q92830 | 2/20 | 0.73 |
| ▸ | BPTF | Q12830 | 2/20 | 0.73 |
| ▸ | BRD1 | O95696 | 1/20 | 0.73 |
| ▸ | ACHE | P22303 | 1/20 | 0.73 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.73 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.73 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.73 |
| ▸ | BRPF3 | Q9ULD4 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30830560 | 1.00 | KAT2B (0.73) | KAT2BBRD9KAT2ABPTFBRD1 | |
| SCHEMBL31091698 | 0.91 | KAT2B (0.68) | KAT2BBRD9KAT2ABPTFBRD1 | |
| SCHEMBL30830559 | 0.90 | KAT2B (0.79) | KAT2BBRD9KAT2ABPTFBRD1 | |
| SCHEMBL30830923 | 0.88 | KAT2B (0.56) | KAT2BBRD9KAT2ABPTFBRD1 | |
| SCHEMBL23682853 | 0.85 | KAT2B (1.00) | KAT2BBRD9KAT2ABPTFBRD1 | |
| SCHEMBL23682859 | 0.85 | KAT2B (1.00) | KAT2BBRD9KAT2ABPTFBRD1 | |
| SCHEMBL30830719 | 0.84 | KAT2B (0.51) | KAT2BBRD9KAT2ABPTFBRD1 | |
| SCHEMBL30830503 | 0.84 | KAT2B (0.76) | KAT2BBRD9KAT2ABPTFBRD1 | |
| SCHEMBL25445787 | 0.83 | KAT2B (0.77) | KAT2BBRD9KAT2ABPTFBRD1 | |
| SCHEMBL30830606 | 0.83 | KAT2B (0.77) | KAT2BBRD9KAT2ABPTFBRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4581025-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Auron Therapeutics, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024220843-A1 | TECHNOLOGIES TARGETING CELL STATES | AURON THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024050078-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AURON THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | WO | disclosed |